Ex-AstraZeneca exec appointed to Takeda advisory board
This article was originally published in Scrip
Executive Summary
Bruno Angelici has been appointed to Takeda's global advisory board, effective 1 October. The former AstraZeneca Japan president and AstraZeneca executive vice-president, international, replaces Dr Frank Morich, who took up a position the same day as executive vice-president of Takeda's international (Americas and Europe) operations. The board was formed in mid-2009 to help guide the Japanese firm's international business and project development strategy.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.